DNA Repair Mechanisms in Cancer: Focus on Homologous Recombination Deficiency (HRD) and Its Oncologic Significance

Maintenance of genomic integrity is fundamental to cellular survival. Cells are continuously exposed to endogenous and exogenous sources of DNA damage, necessitating a sophisticated network of DNA damage response (DDR) and repair pathways. In cancer, defects in these pathways are both a driver of tumorigenesis and an actionable therapeutic vulnerability. Among these defects, homologous recombination deficiency (HRD) has emerged as a critical biomarker and treatment determinant, particularly in solid tumors.

This article provides an overview of DNA repair mechanisms, with a focused discussion on HRD, its molecular basis, and its clinical implications in oncology.

Overview of DNA Damage and Repair Pathways

DNA damage can manifest as base lesions, single-strand breaks (SSBs), or double-strand breaks (DSBs). To address these lesions, cells employ several conserved repair mechanisms:

• Base excision repair (BER): repairs small base modifications and SSBs

• Nucleotide excision repair (NER): removes bulky adducts and helix-distorting lesions

• Mismatch repair (MMR): corrects replication errors

• Non-homologous end joining (NHEJ): error-prone repair of DSBs

• Homologous recombination repair (HRR): high-fidelity repair of DSBs using a sister chromatid

Among these, HRR is particularly important for preserving genomic stability during DNA replication.

 Homologous Recombination Repair: A High-Fidelity Pathway

Homologous recombination repair operates predominantly in the S and G2 phases of the cell cycle, when a sister chromatid is available as a repair template. The process involves coordinated action of multiple proteins, including BRCA1, BRCA2, RAD51, and PALB2.

Key steps include:

1. Resection of DSB ends

2. RAD51 nucleoprotein filament formation

3. Strand invasion and homology search

4. DNA synthesis and resolution

Loss of HRR function results in reliance on error-prone repair pathways, leading to genomic instability, a hallmark of cancer.

What Is Homologous Recombination Deficiency (HRD)?

HRD refers to the inability of a cell to effectively repair DSBs via homologous recombination. While germline or somatic mutations in BRCA1/2 are the most well-known causes, HRD can arise from multiple mechanisms:

• Germline or somatic mutations in other HR-related genes (e.g., PALB2, RAD51C/D)

• Epigenetic silencing of HR genes (e.g., BRCA1 promoter methylation)

• Functional loss due to oncogenic signaling or replication stress

Importantly, HRD is a phenotype, not solely a genotype, and can be detected through genomic “scars” reflecting accumulated DNA damage.

HRD and Genomic Instability

Tumors with HRD exhibit characteristic genomic features, including:

• Loss of heterozygosity (LOH)

• Telomeric allelic imbalance

• Large-scale state transitions

These features form the basis of HRD scoring assays, which are increasingly used to identify patients who may benefit from targeted therapies.

Genomic Scars and HRD Testing

HRD-positive tumors accumulate characteristic genomic alterations, including:

• Loss of heterozygosity (LOH)

• Telomeric allelic imbalance

• Large-scale chromosomal transitions

These features underpin HRD scoring assays, which are increasingly incorporated into clinical decision-making for targeted therapies.

Tumor Types Commonly Associated with HRD

HRD is most prevalent and clinically validated in:

• ovarian cancer

• breast cancer

• prostate cancer

• pancreatic cancer

Emerging data suggest that HRD-directed therapies may also benefit patients without BRCA mutations but with functional HR impairment.

Beyond BRCA-mutant tumors, expanding evidence supports the benefit of HRD-directed therapies in BRCA wild-type but HRD-positive cancers, reinforcing the importance of functional HRD assessment.

Therapeutic Implications: Synthetic Lethality

The clinical relevance of HRD is most clearly demonstrated by the success of PARP inhibitors. Poly(ADP-ribose) polymerase (PARP) enzymes are essential for repairing SSBs. Inhibition of PARP in HR-deficient cells leads to collapse of replication forks and accumulation of lethal DSBs, a concept known as synthetic lethality.

Approved PARP inhibitors such as olaparib, niraparib, and rucaparib have transformed treatment paradigms in several cancers.

These treatment exploits a specific weakness in certain cancer cells, causing them to die while leaving most normal cells unharmed, making it a targeted therapy.

Challenges and Future Directions

Despite clinical advances, several challenges remain:

• Tumor heterogeneity and HRD reversibility

• Development of resistance to PARP inhibitors (e.g., BRCA reversion mutations)

• Standardization and clinical interpretation of HRD assays

Future strategies include rational combination therapies (e.g., PARP inhibitors with immune checkpoint blockade or ATR inhibitors) and improved biomarkers to capture dynamic HR status.

How is HRD Analyzed with NGS?

In Next-Generation Sequencing (NGS), Homologous Recombination Deficiency (HRD) is analyzed through a dual-pronged approach that assesses both the causes (specific mutations) and the consequences (genomic "scars") of the repair defect. 

1. Analysis of Causal Variants (Genetic Testing) 

NGS panels sequence specific genes in the Homologous Recombination Repair (HRR) pathway to identify pathogenic mutations. 

• Targeted Genes: Primary focus is on BRCA1 and BRCA2. Expanded panels may include others such as ATM, PALB2, CHEK2, RAD51, and BARD1.

• Variant Types: Algorithms detect Single Nucleotide Variants (SNVs), small Indels (insertions/deletions), and large genomic rearrangements. 

2. Analysis of Genomic Scars (Genomic Instability)

When HRR is deficient, the cell uses error-prone repair mechanisms, leaving permanent "scars" across the genome. NGS software calculates a Genomic Instability Score (GIS) or HRD Score by quantifying three specific patterns: 

• Loss of Heterozygosity (LOH): Permanent loss of one of the two alleles (parental copies) at a genetic locus.

• Telomeric Allelic Imbalance (TAI): A high number of allelic imbalances extending to the telomeres (ends of chromosomes).

• Large-Scale State Transitions (LST): Chromosomal breaks or crossovers between adjacent segments of at least 10 megabases. 

3. NGS Methodologies & Tools

• Data Input: Analysis can be performed on targeted gene panels, Whole Exome Sequencing (WES), or shallow Whole Genome Sequencing (sWGS).

• SNP Analysis: Modern assays utilize thousands of Single Nucleotide Polymorphisms (SNPs) distributed across the genome to determine copy number variations and allelic imbalances.

• Bioinformatics Tools: Dedicated software like scarHRD or proprietary platforms automate the calculation of these scores from raw sequencing data. 

4. Interpretation of Results

A tumor is typically classified as HRD-positive if it meets either of the following criteria: 

• A pathogenic or likely pathogenic mutation is found in BRCA1 or BRCA2.

• The composite GIS (sum of LOH + TAI + LST) exceeds a validated threshold, commonly ≥ 42.

Conclusion

HRD represents a convergence point between cancer biology and precision oncology. Understanding the molecular basis of homologous recombination and its disruption not only provides insight into tumor evolution but also enables targeted therapeutic intervention. As diagnostic tools and treatment strategies continue to evolve, HRD will remain a cornerstone of personalized cancer care.

Take-Away Messages

Core Concept
Homologous recombination deficiency (HRD) is a functional defect in high-fidelity DNA double-strand break repair that drives genomic instability and therapeutic vulnerability in cancer.

Clinical Relevance
HRD is a validated biomarker for response to PARP inhibitors and is clinically actionable across ovarian, breast, prostate, and pancreatic cancers.

Key Insight
HRD extends beyond BRCA mutations and can be identified through genomic scar signatures, enabling treatment stratification in BRCA wild-type tumors.

Oncology Impact
Understanding and detecting HRD supports precision oncology by aligning DNA repair biology with targeted treatment strategies based on synthetic lethality.

Future Direction
Dynamic assessment of HRD and rational combination therapies will expand its clinical utility and overcome resistance mechanisms.